Spurred, in part, by concerns over contaminated heparin products produced with Chinese ingredients, the US Food and Drug Administration (FDA) is taking steps to expand its presence in the People's Republic of China.
The agency has received approval from the US State Department to establish 8 full-time permanent FDA positions at US diplomatic posts in China and is awaiting approval of the move from Chinese officials. The agency also plans to hire 5 Chinese nationals to work with the new FDA staff members, who will be based in Beijing, Shanghai, and Guangzhou. The changes are expected to take place over the next 18 months.
Kuehn BM. FDA to Boost Its Presence in China. JAMA. 2008;299(15):1762. doi:10.1001/jama.299.15.1762